Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin plus carboplatin/paclitaxel in advanced ovarian cancer
NL-OMON40143Phase 2Recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Oct 2015
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of metformin, carboplatin and paclitaxel in ovarian cancer and epithelial ovarian cancer (EOC) (3 arms), sponsored by University Medical Center Groningen. Primary endpoints: Recommended phase II dose and Objective response rate / CA-125 response. Started Oct 2015; status: recruiting.
02
Drugs
metformincarboplatinpaclitaxel
03
Conditions
ovarian cancerepithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on NL-OMON40143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40143.